Skip Nav Destination
Content Menu
-
References
CLINICAL TRIALS AND OBSERVATIONS| October 20, 2022
Clinical Trials & Observations
Fabian Frontzek,
Fabian Frontzek
University Hospital Münster
Search for other works by this author on:
This Site
Georg Lenz
Georg Lenz
University Hospital Münster
Search for other works by this author on:
This Site
Blood (2022) 140 (16): 1751–1752.
- Split-Screen
- Tools Icon Tools
Cite Icon Cite
- Search Site
- Open the PDF for in another window
Citation
Fabian Frontzek, Georg Lenz; Tackling ALK-positive LBCL. Blood 2022; 140 (16): 1751–1752. doi: https://doi.org/10.1182/blood.2022017742
Download citation file:
- Ris (Zotero)
- Reference Manager
- EasyBib
- Bookends
- Mendeley
- Papers
- EndNote
- RefWorks
- BibTex
Subjects:
Free Research Articles
In this issue of Blood, Soumerai etal present the first patient-derived xenograft (PDX) mouse models of anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) to investigate novel therapeutic approaches for this rare aggressive lymphoma subtype.1 The authors show that the next-generation ALK inhibitors alectinib and lorlatinib have promising activity in these preclinical invivo PDX models and in intensively pretreated patients with relapsed/refractory ALK-LBCL.
ALK-LBCL is a very rare aggressive B-cell lymphoma subtype with immunoblastic-plasmablastic morphology.2 The lymphoma cells are characterized by plasmacytic differentiation lacking expression ofclassical B- and T-cell markers. Thus, ALK-LBCLs belong to the rare group of CD20− B-cell lymphomas.3 ALK-LBCLs are further characterized by strong granular cytoplasmic expression of ALK, caused by oncogenic ALK gene fusions, with the t(2;17) translocation being the most frequently detected genetic aberration.4 Overall, only a few cases and small retrospective series of patients with ALK-LBCL have been reported in the literature. Following conventional cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone-based front-line chemotherapy, patients with ALK-LBCL frequently relapse with dismal outcomes.3 Treatment of patients with relapsed/refractory disease with the ALK inhibitor crizotinib was reported to induce only short-term remissions.5 Therefore, a significantly better understanding of the biology of this entity is required to develop novel therapeutic approaches for these high-risk patients.
Soumerai etal succeeded in creating the first PDX models of ALK-LBCL by implanting lymphoma cells from ALK-LBCL refractory patients in nonobese diabetic scid γ mice. Engrafted lymphomas maintained the same oncogenic molecular alterations detected in the primary lymphoma tissue. Treatment with the next-generation ALK inhibitors lorlatinib and alectinib resulted in significant tumor inhibition when compared with mice treated with vehicle only. Remarkably, these encouraging results were directly translated into the clinic by consecutively treating four refractory ALK-LBCL patients with alectinib. Intriguingly, 3 of 4 patients achieved a complete remission, with 2 patients maintaining response following allogeneic stem cell transplantation. Notably, the 1 patient who showed progressive disease after treatment with alectinib, monotherapy with the third-generation ALK inhibitor lorlatinib induced a complete remission.
This manuscript impressively illustrates how PDX models can be used to test noveltherapeutic strategies for rare diseases and how these results can successfully be translated into clinical practice. Thepromising effect of the ALK inhibitorslorlatinib and alectinib, first discovered inthe established PDX models, induced complete remissions in refractory ALK-LBCL patients. Although tumors mayquickly evolve when passaged severaltimes, comprehensive analyses have previously shown the reproducibility and translatability of PDX models.6 Particularly for rare cancer entities, PDX models provide an important tool to explore the underlying biology and to evaluate novel targeted therapies.
At this stage, the molecular mechanisms that cause acquired crizotinib resistance and how the next-generation ALK inhibitors alectinib and lorlatinib overcome this resistance are still being explored. A genome-wide screen in ALK-positive anaplastic large-cell lymphomas recently revealed that loss of the phosphatases PTPN1 and PTPN2 leads to crizotinib resistance by activating SHP2, JAK-STAT, and MAPK signaling.7 Accordingly, combining ALK- and SHP2-inhibitors synergistically inhibited wild-type as well as PTPN1/PTPN2 knockout ALK-positive anaplastic large-cell models.7 Whether the same molecular mechanisms also are involved in crizotinib resistance in ALK-LBCLs is currently unknown. Thus, a better molecular understanding will be key to further improve targeted therapies in ALK-LBCLs.
Although the findings hold great potential to improve outcome of patients with ALK-LBCL, these results need to be further confirmed in larger patient cohorts, ideally within prospective clinical trials. This, however, will only be possible with a major international effort due to the rarity of the disease. Therefore, international networks and close collaborations are crucial to overcome this obstacle and to further improve both our understanding of the molecular pathogenesis of ALK-positive LBCL as well as treatment strategies for affected patients.
Conflict-of-interest disclosure: G.L. received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Morphosys, Novartis, Roche, and Verastem and received honoraria from ADC Therapeutics, Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Constellation, Genmab, Gilead, Incyte, Janssen, Karyopharm, Miltenyi, Morphosys, NanoString, Novartis, and Roche. F.F. declares no competing financial interests.
References
1.
Soumerai JD Rosenthal A Harkins SK
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
.
Blood
.
2022
;
140
(
16
):
1822
-
1826
.
2.
Swerdlow SH Campo E Harris NL
Lyon, France
:
IARC
;
2017
.
3.
Laurent C Do C Gascoyne RD
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis
.
JClin Oncol
.
2009
;
27
(
25
):
4211
-
4216
.
4.
Gascoyne RD Lamant L Martin-Subero JI
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
.
Blood
.
2003
;
102
(
7
):
2568
-
2573
.
5.
Wass M Behlendorf T Schädlich B
Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response
.
Eur J Haematol
.
2014
;
92
(
3
):
268
-
270
.
6.
Gao H Korn JM Ferretti S
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
.
Nat Med
.
2015
;
21
(
11
):
1318
-
1325
.
7.
Karaca Atabay E Mecca C Wang Q
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
.
Blood
.
2022
;
139
(
5
):
717
-
731
.
© 2022 by The American Society of Hematology
2022
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Comment not saved. Please try again.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal
October 20 2022
- Previous Article
- Next Article
Advertisem*nt
View Metrics
Cited By
Google Scholar
Email alerts
Article Activity Alert
First Edition Alert
Latest Issue Alert
Close Modal
Advertisem*nt